Aditxt Inc (ADTX) Stock Price, Trades & News

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues. The company operates in one segment, which is focused on the discovery and development of biopharmaceutical products.

Financial Strength

Name	Current	Vs Industry
Cash-To-Debt	0.06
Equity-to-Asset	-2.39
Debt-to-Equity	-0.13
Debt-to-EBITDA	-0.08
Piotroski F-Score	2/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	-35.87	Distress Grey Safe
Beneish M-Score	-28.21	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	26.98
	9-Day RSI	10.58
	14-Day RSI	13.71
	3-1 Month Momentum %	-98.93
	6-1 Month Momentum %	-99.89
	12-1 Month Momentum %	-100

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.06
	Quick Ratio	0.05
	Cash Ratio	0.02
	Days Inventory	1048.55
	Days Sales Outstanding	1877.14
	Days Payable	277181

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Shareholder Yield %	-1045.44

Profitability Rank

	Name	Current	Vs Industry		Vs History
	Gross Margin %	21.43
	Operating Margin %	-130892.86
	Net Margin %	-371085.71
	EBITDA Margin %	-362071.43
	FCF Margin %	-132607.14
	OCF Margin %	-132535.71
	ROA %	-244.74
	ROIC %	-67.27
	3-Year ROIIC %	56.2
	ROC (Joel Greenblatt) %	-2369.79
	ROCE %	-1054.55
	Moat Score	2
	Tariff Resilience Score	4

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	0.01
	EV-to-EBIT	-0.08
	EV-to-Forward-EBIT	0.48
	EV-to-EBITDA	-0.08
	EV-to-Revenue	297.43
	EV-to-Forward-Revenue	9.72
	EV-to-FCF	-0.22
	Earnings Yield (Greenblatt) %	-1250
	FCF Yield %	-885.73

GF Value™

ADTX

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with ADTX. Try a 7-Day Free Trial to check it out.

Aditxt Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Aditxt Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings results for 2026	2026-11-18	In 142 days
Second quarter earnings results for 2026	2026-08-14	In 46 days
First quarter earnings results for 2026	2026-05-20	1.52 (+2.01%)
0.037037:1 Stock Split	2026-05-18	1.73 (-8.43%)
General meeting for 2026	2026-05-01 12:00	5.27 (-11.36%)
Annual report for 2025	2026-03-31	21.31 (-6.60%)
0.125:1 Stock Split	2026-03-09	100.57 (+10.86%)
Third quarter earnings results for 2025	2025-11-18	915.84 (-9.01%)
0.00884956:1 Stock Split	2025-11-03	1,449.83 (-12.52%)
General meeting for 2025	2025-09-16 12:00	24,212.72 (-1.78%)

Show

Entries

Guru Commentaries on OTCPK:ADTX

No articles.

Press Release

	Subject	Date
	Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million	2026-06-09
	Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection	2026-06-08
	Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders	2026-06-01
	Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients	2026-04-20
	Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer	2026-03-19
	Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection	2026-03-13
	Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026	2026-03-05
	Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing	2025-11-18
	Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025	2025-10-29
	Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative	2025-08-11

10/Page

Articles on Aditxt Inc

No articles.

Headlines

Jun 18, 2026

Nasdaq Surges 300 Points; US Initial Jobless Claims Edge Lower

Benzinga • 9:53am

Jun 17, 2026

Crude Oil Edges Higher; US Retail Sales Top Estimates

Benzinga • 11:06am

Jun 12, 2026

Aditxt (ADTX) Stock Surges Nearly 17% After Hours: Here's Why

Benzinga • 2:17am

Jun 10, 2026

What's Going On With Aditxt Stock Wednesday?

Benzinga • 6:56am

Jun 01, 2026

Aditxt appoints Jeffrey M. Busch as interim CEO

Seeking Alpha • 8:28am

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.